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ilar between the groups. 
Conclusion: These data suggest that in patients undergoing PCI, the smoker’s paradox is 
an artifact that can be accounted for by younger age and less severe underlying disease 
among smokers rather than a true benefit of smoking. 
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Background: Myocardial necrosis (Ml) after percutaneous coronary intervention (PCI) IS 
associated with an increased incidence of late adverse outcomes. Methods: We con- 
ducted a prospective randomized. placebo-controlled trial in 150 PCI patients to deter- 
mine whether intracoronary (IC) propranolol ( 0.015mglkg) decreases post - PCI MI and 
in which subgroups this effect occurs. Results: Post -PCI Ml &K-MB > upper limit of nor- 
mal) developed in 17% of IC propranolol pts (13/75) and 36% of placebo pts ( 27175) 
(p=O.Ol). The figure shows that this effect is widely applicable including the subgroup 
receiving prophylactic GP llbillla inhibitors (28% of pts) and chronic oral pre-PCI beta- 
blockers (64%). Factors associated with decreased risk of MI were IC propranolol (OR: 
0.40, Cl: 0.17-0.91, p= 0.03) and prophylactic GP Ilb/llla use (OR: 0.41, Cl: 0.14-I .08, p= 
0.08). IC propranolol decreased MIS in GP llblllla pts ( O%vs. 41%) and pts on chronic 
beta blockers ( 16% vs. 35%).Factors associated with increased Ml were age > 60 years 
old and mechanical complications during PCI. IC propranolol decreased MI risk in older 
pts (19% vs. 46%) and in patients with mechanical complications (41% vs. 61%). Con- 
clusion: These data are consistent with IC propranolol being a broadly effective cardio- 
protective agent during PCI. 
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Interventions by Hyperbaric Oxygen Therapy 
Mohsen Sharifr Wassim Fares, lsam Abdel-Karim, Dan Petrea, Michael Koch, Dale S. 
Adler, Vincent J. Pompili, Joseph Sopko, St. Vincent Charity Hospital, Cleveland, OH, 
Case Western Reserve University, Cleveland, OH 
Background: Hyperbaric Oxygen Therapy (HOT)is a potent modality in the management 
of slow healing wounds.Percutaneous Coronary Interventions(PCl)uniformly create min. 
iature wounds by the disruptive effects of the interventional hardware,thereby triggering 
the humoro-cellular responses leading to restenosis.lt is intriguing to postulate that early 
healing of these miniature wounds by HOT may decrease restenosis.The following con- 
stitutes our interim comparative flndings. 
Methods: Of 68 patients Initially enrolled,28 were randomized to the HOT arm and 40 to 
the control group.The patients underwent PCI for unstable angina or acute myocrdial inf- 
arction(Ml) .All patients received at least one stent.Patients in the HOT arm underwent 2 
hyperbaric dives using the Sechrist 25008 MonoplaceSystem(Sechrist Inds., Anna- 
heim,CA):one dive 2 hours before or immediately after PCl,and the other withtn 18 hours 
of the first dive.Each dive consisted of 100% Oxygen at 2 bars for 90 minutes. 
Results: The primary endpoints consisted of major adverse cardiac events at 8 
months(Table).Repeat coronary angiography was performed for chest pain or Ml in 3 
patients of the HOT arm and 8 of the control group.Anglographlc restenosis in the target 
lesion was found in 7of the control and 0 of the HOT arm(p=0.007). 
Conclusions: HOT is a safe and effective adjunct to PCI and IS associated with a signdi- 
cant reduction I” the restenosls rate.Furthermore,it substantially reduces recurrence of 
late angina1 symptoms. 
Adverse Events at 8 Months 
HOT Control p Value 
No=28 No=40 
Composite Endpoints:Death, MI,CABG,TLR 1 IO p=O.O23 
Death 0 2 NS 
Ml 1 5 NS 
CABG 0 0 NS 
TLR 0 6 ~~0.036 
Recurrent Angina 0 8 p=o.o14 
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Background: Preliminary data suggest that systemic inflammation may influence the 
clinical course following percutaneous coronary intervention (PCI). The relationship 
between inflammation at baseline and periprocedural myocardial infarction (Ml) has not 
been well explored. Methods: We examined the effect of systemic inflammation at base- 
tine (white blood cell count [WBC]) on the incidence of Ml (CKMB > 3x upper limit of nor- 
mal) after elective PCI among high-risk patients without recent acute coronary 
syndromes from the EPIC study (n=880). Results: Overall, Ml occurred in 146 (16.6%). 
The incidence of Ml in the 1”: Znd and 3” WBC tertiles was 6.5, 9.6 and 13.8%, respec- 
tively (p for trend O.OOlMS) [Figure]. In a multivariable logistic regression model, increas- 
ing WBC count (OR for each lOOO/uL increase 1.136 [95% Cl 1.049-1.231]. p=O.O02) 
was independently associated with a higher risk of peri-procedural Ml. Conclusion: Pre 
procedure inflammatory state predisposes patients to peri-procedural Ml. A randomized 
trial comparing immediate PCI versus PCI deferred for anti-inflammatory pre-treatment 
(e.g., statins) appears warranted. 
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Adenosine (ADO), used for diagnostic purposes, is supposed to exhaust myocardial 
resistance (MR). In patients (pts) with coronary artery disease, alpha vasomotor tone is 
enhanced and ADO might fail to reach minimal MR. 
To determine the presence of clinically relevant residual MR after ADO administration. 
Fractional flow reserve (FFR=hyperemic Pd/Pa, where Pa is mean aortic pressure and 
Pd mean distal coronary pressure) was assessed in. a) Gr I, 13 coronary s&noses 
(51*12 %, Diameter Stenosis) of 13 pts. during IC bolus of ADO, before and 3 min after 
IC bolus of phentolamine (PHE, 1 mg), an alpha I-. alpha 2-adrenergic blacker, b) Gr 2, 
12 stenoses (48~11 %, DS) of 12 pts. during IV infusion of ADO, and during IV ADO plus 
PHE (PHE 1 mg, given on top of maximal ADO hyperemia); c) Gr 3, 8 stenoses of 8 pts 
(44r5 %. DS), during IV ADO, and during IV ADO plus high dose PHE (PHE 3 mg); d) Gr 
4, 13 stenoses (5Oi13 %, DS) of 13 pts, during IC ADO, before and 3 min after IC bolus 
of urapidil (URA, IO mg). an alpha I-adrenergic blocker; e) Gr 5, 13 stenoses (5OklO %, 
DS) of 13 pts, during IV ADO, and during IV ADO plus URA. All pts received IC isosor- 
bide dinitrate (ISDN, 3 mg) at the beginning of the protocols. All pts had normal left ven- 
tricular function. 
Since epicardial stenosis remained unchanged (MLD before vs. after, Gr 1: 1,25~0,42 vs. 
1,33+0,39, “s; Gr2: 1,48~0,22”s. 1,44*0,38, “s; Gr3: 1,47+O,lOvs. 1,53*0,16, ns; Gr 
4: 1,52*0,15 vs 1,44*0,15, ns; Gr 5: 1,41*0,13 vs. 1,36iO,lO. ns), changes in PdiPa 
ratio reflect changes in MR. With IC ADO, Pd/Pa ratio did not change before and after 
PHE (0.79iO.04 vs. 0.79+0.04, ns). A slight decrease in Pd/Pa ratio was observed after 
URA (0.78*0.03 vs. 0.76+0.03, ~~0.05). During IV ADO, Pd/Pa ratio remained constant 
before and after PHE (0.79iO.03 vs. 0.77*0.03. ns) and even at h!gh dose PHE 
(0.78r0.04 vs. 0.76r0.05, ns). A small decrease was observed after URA (0.77*0.03 vs. 
0.74iO.03, ~~0.05). Neverthless, only 4 pts had a significant decrease I” PdiPa ratio. 
PHE and URA administratlon induced only transient changes in heart rate and in blood 
pressure. 
In the diagnostic setting, when given on top of ADO, URA (but not PHE) induces a limited 
further decrease in MR. Yet this changed the clinical decision in only 7 % of pts. 
